Scott Kopetz, MD, PhD, discusses the treatment of patients with colorectal cancer and how it differs from other cancer regimens.
Scott Kopetz, MD, PhD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses the treatment of patients with colorectal cancer (CRC) and how it differs from other cancer regimens.
Kopetz says that the data in the CRC trials is looking at how to optimally treat patients. Patients with aBRAFV600E mutation should be treated in a different manner than other types of cancer, and that aggressive chemotherapy may be effective at first, but the duration of benefit from standard cytotoxic chemotherapy is less than what is seen in other patients with cancer, according to Kopetz.
Figuring out how to target theBRAFmutation directly is a key part of deciding on treatment. Kopetz thinks that this patient population is a distinct entity compared to others in oncology on a biologic level because of the precursor lesions, the polyps in the tumors, and the carcinogenic pathways activated are all different. The clinical outcomes are also different for patients withBRAFV600E-mutated CRC, which makes it a distinct subgroup of CRC.
Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback
July 18th 2024Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More